Targets › INHBE
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Oct 2027.
Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth,…. (UniProt, P58166)
Open in Phaseline: the race on INHBE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | ARO-INHBE INHBE inhibitor (RNA interference) | INHBE | Phase 1 | Obesity | Oct 2027 |
Obesity (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.